adjuvant chemotherapy is correlated with better RFS and OS irrespective of the regimens, while the incidence of severe adverse event was significantly different between UFT/LV and oxaliplatin (6.8 vs. 50.9%, p < 0.0001). Conclusion: Adjuvant chemotherapy might improve the clinical outcomes in S-CLM and EM-CLM. UFT/LV might be a choice for CLM in adjuvant settings in selected patients.
Introduction
Hepatic resection is acknowledged to be the most effective treatment for patients with colorectal liver metastases (CLM) [1, 2] . With recent dramatic advancements in systemic therapies for colorectal cancer (CRC), it has been reported that chemotherapy followed by an aggressive surgical approach as a part of multidisciplinary treatment may improve the long-term outcomes in selected patients with CLM [2] [3] [4] . However, the use of adjuvant systemic therapy for CLMs remains controversial.
As for primary CRC, many trials have revealed that adjuvant chemotherapy after surgery improves the outcome of patients with stages II or III CRC and its prognostic benefit has been established. For patients with CLM, however, only limited evidence is available. To date, several studies have reported that adjuvant chemotherapy prolonged recurrence-free survival (RFS) after resection of CLM using 5-fluorouracil with leucovorin (5-FU/LV) [5] , FOLFOX [4] , or uracil-tegafur (UFT; Taiho Pharmaceutical Co. Ltd., Tokyo, Japan), an oral 5-FU preparation combining tegafur and uracil, with LV (UFT/LV) [6] ; however, none of them could show the improvement in overall survival (OS). Nevertheless, because of the high relapse rate even after the curative resection of CLM [7] , adjuvant chemotherapy has been widely used in actual clinical settings considering the resected tumor burden or the performance status of patients.
In actual clinical settings, patients who are considered to be at high risk of recurrence can be candidate for adjuvant chemotherapy. Disease-free interval (DFI) from resection of primary lesion can be a factor estimating the risk of recurrence after heaptectomy for CLM [8] . However, definitions of synchronous and metachronous presentation vary among studies [4, 6] and its influence on the efficacy of adjuvant chemotherapy has not well been studied so far.
The objective of this study was to investigate the efficacy of adjuvant chemotherapy for patients undergoing hepatic resection for CLM stratified by chemotherapy regimens and DFI.
Materials and Methods

Study Population
We carried out a search of a prospectively collected database at Toranomon Hospital between January 2008 and June 2016, and identified 227 patients who underwent curative surgical resection for CLM. Of these, 104 patients did not receive any adjuvant therapy and 123 patients received adjuvant chemotherapy after hepatic resection. Forty-seven patients were administered with UFT/ LV, 58 patients underwent oxaliplatin-based chemotherapy; 28 patients were given FOLFOX, and 30 were given CapeOX. The remaining 18 patients, who received postoperative chemotherapy in other hospitals (7 patients) or those who received the other agents (capacitabilin, n = 6; S-1, n = 2, irinotecan, n = 1; bevacizumab, n = 1; panitumumab, n = 1) were excluded and 209 patients were finally included in the analysis. All the analyses in the current study were performed in accordance with the ethical guidelines for clinical studies at Toranomon Hospital with the approval of the institutional review board.
The study population was stratified by DFI as follows: synchronous CLM (S-CLM), CLM detected at or before diagnosis of the primary tumor; early metachronous CLM (EM-CLM), EM-CLM with DFI ≤1 year; late metachronous CLM (LM-CLM), CLM with DFI >1 year. Major hepatectomy was defined as hepatic resection 3 or more Couinaud's segments. R0 resection was defined as microscopically negative surgical margins, and R1 resection as very narrow surgical margins (<1 mm). Major complication was defined as complication classified into grade 3 or more in ClavienDindo classification.
Adjuvant Chemotherapy
Adjuvant chemotherapy was started within 3 months after curative hepatic resection. Selection of chemotherapy regimen or initial dose reduction was determined by physician's preference considering the performance status of the patients, resected tumor burden, and patients' request about route of administration.
In patients administered with UFT/LV, UFT (300 mg/m 2 /day as tegafur) and LV (75 mg/day) were simultaneously administered every day for 6-18 months after surgery as previously described [9] . In patients with oxaliplatin, either FOLFOX4 or FOLFOX6 or CapeOX was used for 6 months, according to a former study [10] . Adjuvant therapy was stopped (1) when recurrence was observed, (2) when a patients developed unmanageable toxicity, or (3) when a patient refused to continue chemotherapy.
The Evaluation of Safety
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events, version 4.0. The worst grade of each adverse event was recorded. The decision to reduce the dose of agents by adverse events was left to each doctor. The relative dose intensity (RDI) of UFT/LV or Oxaliplatin was calculated as follows: RDI = total administered dose divided by the total scheduled dose × 100 (%).
Statistical Analysis
Categorical variables were compared using the χ 2 test or Fisher's exact test and continuous variables were compared using the Kruskal-Wallis or Mann-Whitney U test as appropriate. The OS period and the RFS period were determined from the date of hepatic resection until the date of death or the initial tumor recurrence, respectively. All the cases without specific prognostic events were censored at the date of the last follow-up examination. The survival curves were generated using the Kaplan-Meier method and were compared using a log-rank test.
To investigate the prognostic factors, the influence of 13 items was assessed in univariate analysis using the Cox proportional hazards model: age (≤60 or >60), gender, primary tumor location, primary tumor nodal status, CEA before hepatic surgery (≤5 or >5 ng/ mL), CA19-9 before hepatic surgery (≤40 or >40 ng/mL), adjuvant chemotherapy after the primary resection, neoadjuvant chemotherapy before hepatic surgery, number of liver metastases (1, 2-4, 5≤), tumor size (>5 or ≤5 cm), surgical procedure (major hepatectomy or minor hepatectomy), surgical margin, and the regimen of adjuvant chemotherapy after hepatic surgery. Variables with p < 0.1 were included in the Cox multivariate model. p < 0.05 was set as indicating a statistically significant difference. Statistical analyses were performed using the JMP software (version 11.0; SAS Institute Inc., USA).
Results
Patient Characteristics
As shown in Table 1 , the study cohort included 152 men (72.7%) and 57 women (27.3%), with a median age of 63 years (range 35-88 years). The primary tumor was in the colon in 125 patients (59.8%) and in the rectum in . Forty-four patients (21.1%) underwent major hepatectomy, and 23 patients (11.0%) experienced major morbidity. R0 resection were obtained in 160 patients (76.6%), while the other cases exhibited very narrow surgical margins (<1 mm) (R1 resection). There were no patients who underwent staged surgery, ablation therapies, or the other anti-cancer treatment. When compared to patients with no adjuvant chemotherapy, those who underwent adjuvant chemotherapy tended to be elder (median 65 vs. 63, p = 0.014); however, there was no statistical difference in the other profile. The mean observation period was 28 months for patients without adjuvant chemotherapy and 48 months for those who underwent adjuvant chemotherapy (p < 0.001), reflecting the decreased rate of adjuvant chemotherapy from 58% before 2014 to 31% after 2015 in the current population due to lack of solid evidence for adjuvant therapy. The number of patients censored was 69 (66.4%) in patients without adjuvant therapy and 71 (67.6%) in those with adjuvant therapy, respectively (p = 0.845). The number of patients lost to follow-up was 9 (8.7%) in patients without adjuvant therapy and 14 (13.3%) in those with adjuvant therapy, respectively (p = 0.278).
Feasibility of Adjuvant Chemotherapy
The proportion of patients who completed the scheduled adjuvant chemotherapy was higher in the UFT group (84.1%) than that in the OX group (44.6%; p < 0.001), although there was no statistical difference of RFS or OS between patients with/without completion of scheduled adjuvant chemotherapy in both UFT/LV and oxaliplatin-based regimen group. Severe adverse events (grades 3 or 4) were significantly frequent in the OX group (50.9%) compared to the UFT group (6.8%; p < 0.001). The RDI was 95.0 ± 4.1% in the UFT group and 84.8 ± 5.2% in the OX group (p = 0.004), respectively. Figure 1 shows RFS of patients with/without adjuvant chemotherapy stratified by DFI (i.e., S-CLM, EM-CLM, and LM-CLM). Five-year RFS rates were 11.2% in patients with no adjuvant chemotherapy, 32.8% in those with adjuvant chemotherapy (p = 0.002) in the S-CLM group, 15.2%, 43.7% (p = 0.002) in the EM-CLM group, and 29.6%, 44.1% (p = 0.163) in the LM-CLM group, respectively. Figure 2 shows OS and the 5-year OS rates were 44.5% in patients with no adjuvant chemotherapy, 77.9% in those with adjuvant chemotherapy (p = 0.021) in the S-CLM group, 39.5%, 81.5% (p = 0.015) in the EM-CLM group, and 65.4%, 76.1% (p = 0.411) in the LM-CLM group, respectively. Subsequently, in S-CLM and EM-CLM (i.e., DFI ≤1 year), multivariate analyses of factors associated with As for the regimen of adjuvant chemotherapy in CLM with DFI ≤1 year, RFS and OS in patients who received UFT/LV or oxaliplatin-based regimen are shown in Figure 3 . In patients with DFI ≤1 year, patients who underwent adjuvant chemotherapy showed significantly better RFS and OS regardless of the regimen than those with no adjuvant chemotherapy and there was no difference in both RFS and OS between the UFT/LV group and oxaliplatin-based regimen (regarding RFS, UFT/LV vs. none, p = 0.002; oxaliplatin vs. none, p < 0.001; UFT/LV vs. oxaliplatin, p = 0.942; regarding OS, UFT/LV vs. none, p = 0.008; oxaliplatin vs. none, p = 0.003; UFT/LV vs. oxaliplatin, p = 0.918).
Prognostic Factors in Patients with CLM
Discussion
In this study, we evaluated the prognostic impact of adjuvant chemotherapy using UFT/LV or oxaliplatin after curative hepatic resection for CLM stratified by DFI. Adjuvant chemotherapy prolonged both RFS and OS in CLM with DFI ≤1 year, and both UFT/LV and oxaliplatin had the effect on improving prognosis to the same degree. However, no prognostic advantage of adjuvant chemotherapy was confirmed in CLM with DFI >1 year. UFT/LV was associated with a lower abandon rate and lower adverse effect compared with oxaliplatin-based regimens followed during adjuvant systemic therapy.
It has been reported that hepatic resection significantly improves the outcome of patients with CLMs; however, recurrence occurs in 70-80% of them [7, 11] . Although S-CLM is well known to have less favorable prognosis [12] , DFI ≤1 year is also reported to be a risk factor for poor prognosis and EGOSLIM group classified metachronous CLM with DFI ≤1 year into EM-CLM and the others into LM-CLM [8] .
In patients with stages II or III CRC, adjuvant chemotherapy using UFT/LV [9, 13] or oxaliplatin [14, 15] has been validated to prolong RFS and OS. However, there is only less evidence on the adjuvant chemotherapy for patients with CLM [5] , though both UFT/LV and oxaliplatin have been reported to be feasible in adjuvant settings after hepatic resection [10, 16] .
UFT is an oral 5-FU prodrug and UFT/LV therapy has been reported to be not inferior to 5-FU/LV as adjuvant chemotherapy for stages II or III CRC [13] . It has also been confirmed that adjuvant chemotherapy using oxaliplatin-based regimen may achieve better RFS and OS than 5-FU/LV alone among patients with stages II or III CRC [14, 15] . However, specific adverse events such as neutropenia or sinusoidal injury in the liver might limit the prolonged use of oxaliplatin. In a previous study, the completion rate of postoperative FOLFOX in adjuvant settings was 44% and grades 3 or 4 adverse events were more frequent than the preoperative period [4] . In contrast, it has been reported that UFT/LV is associated with a better continuation rate and milder adverse events [16] , and the current results also confirmed that UFT/LV was associated with a better continuation rate and lower adverse events compared with oxaliplatin-based regimen. There were 2 noteworthy results in this study. First, adjuvant chemotherapy may be associated with better RFS and OS not only in S-CLM but also in EM-CLM. Conventionally, it has been reported that perioperative chemotherapy may not benefit patients with EM-CLM [17] ; however, the present analysis showed that adjuvant therapy may be advantageous also for EM-CLM. Prognostic superiority of EM-CLM would be attributable to the longer observational period from the diagnosis of primary lesion, which might be associated with a reduced risk of occult lesion in the liver. Given that the purpose of adjuvant chemotherapy is to expect eradication of occult lesions remaining in the liver, the current 194 observation suggests that EM-CLM remains harboring a higher risk of latent metastasic lesions compared to LM-CLM. Therefore, EM-CLM can be a candidate for adjuvant therapy after curative resection. Second, patients who received UFT/LV showed outcomes similar to those who underwent oxaliplatin-based regimens after curative resection. Although it is difficult to conclude that UFT/LV may have equivalent efficacy compared to the oxaliplatin-based regimens, one of the advantages of UFT/LV would be lower toxicity in comparison with standard cytotoxic regimens. Hepatic resection is generally an invasive procedure, and accordingly, it is not always feasible to complete the doublet cytotoxic regimen such as FOLFOX or FOLFIRI due to decreased performance status and delayed recovery from surgery as reported in EORTC 40983 [4] . However, as indicated in this study, UFT/LV can be administered at a higher dose intensity and with a higher completion rate. Therefore, UFT/LV could be a choice of adjuvant chemotherapy after curative surgical resection of CLM, especially for elderly patients or those with poor performance status after surgery. The limitations of this study include its retrospective nature, limited number of subjects and ambiguity in selecting the regimen. However, the present analysis was based on a prospectively collected database, and it is important that the current study suggested potential prognostic advantage of adjuvant chemotherapy for patients with CLM with DFI of less than 1 year. External validation using a larger population with adequate statistical methods (e.g., propensity-score adjustment analysis) would be needed to confirm the present results, and the current results may warrant randomized controlled trial comparing UFT/LV and FOLFOX as adjuvant therapy for CLM.
In conclusion, adjuvant chemotherapy using either UFT/LV or oxaliplatin may improve the long-term outcomes after surgery not only in patients with synchronous but also EM-CLM with DFI ≤1year. In adjuvant therapy after hepatic resection, UFT/LV might be a choice of regimen considering its safety and higher feasibility.
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